Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
---|
12/29/2010 | CN101932939A Marker for determination of sensitivity to anti-cancer agent |
12/29/2010 | CN101932338A Method for determination of sensitivity to anti-cancer agent |
12/29/2010 | CN101932321A Combination therapy comprising sglt inhibitors and dpp4 inhibitors |
12/29/2010 | CN101932320A Membrane fusion inhibitor |
12/29/2010 | CN101928706A Technology for regulating up expression of ARE elements in DRD1 (Dopamine Receptor D1) mRNA 3-end non-coding region by stabilizing DRD1 mRNA |
12/29/2010 | CN101928692A Differentiated cells suitable for human therapy |
12/29/2010 | CN101928288A Small molecule compositions for binding to HSP90 |
12/29/2010 | CN101926999A Hemostatic disinfectant and preparation method thereof |
12/29/2010 | CN101926998A Expression of embryo type globin induced by adrenoreceptor agonist and application thereof |
12/29/2010 | CN101926997A Use of angiotensin ii receptor antagonists, especially telmisartan, in order to increase insulin sensitivity |
12/29/2010 | CN101926996A Application of methotrexate and ABC inhibitor to preparation of medicament for treating psoriasis |
12/29/2010 | CN101926783A Drug slow control releaser and preparation method thereof |
12/29/2010 | CN101926773A Medicament-carrying lipoid particulates and preparation method thereof |
12/29/2010 | CN101926770A Drug-loaded liposome and preparation method thereof |
12/29/2010 | CN101417132B Use of medicine combination comprising carvedilol and angiotensin II recipient antagonist in preparing medicine for treating kidney disease |
12/29/2010 | CN101380320B The use of cholinesterase inhibitors in pharmacy |
12/29/2010 | CA2766197A1 Pharmaceutical composition for emergency contraception |
12/29/2010 | CA2764423A1 Preparation comprising insulin, nicotinamide and an amino acid |
12/29/2010 | CA2763299A1 Method for treating or ameliorating mucocutaneous or ocular toxicities |
12/28/2010 | USRE42012 Compositions and methods for enhancing receptor-mediated cellular internalization |
12/28/2010 | US7858662 Medicament for the treatment of viral skin and tumour diseases |
12/28/2010 | US7858659 Redox therapy for tumors |
12/28/2010 | US7858655 synergistic mixtures reduce damage to neurons after a neurodegenerative insult; time-release agents; antiischemic agents; amyotrophic lateral slerosis (ALS), Alzheimer's disease, Parkinson's disease, Hunntington's disease, multiple sclerosis |
12/28/2010 | US7858605 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
12/28/2010 | US7858597 formulations of ANGIOTENSIN II AT1 receptors antagonists, using the cyclodextrins or their derivatives, lipossomes and the biodegradable polymers; increasing the bio-availability of losartan |
12/28/2010 | US7858589 A saponin possessing immune adjuvant activity, derived from Quillaja saponaria; an immunostimulatory oligonucleotide cotaining an unmethylated CpG dinucleotide,wherein the immunostimulatory oligonucleotide is not a part of a DNA vaccine vector |
12/28/2010 | US7858588 Oligodeoxynucleic acid modified with (thio)phosphate |
12/28/2010 | US7858577 Use of the long pentraxin PTX3 for the treatment of diseases caused by an altered activation of the growth factor FGF-2 |
12/28/2010 | US7858312 Method of treating bladder and lower urinary tract syndromes |
12/28/2010 | US7858103 Characterizing inflammatory mediator for use in generating antibodies for prevention and treatment of helicobacter infection; immunotherapy |
12/28/2010 | US7858094 Controling abberant inflamatory response; obtain animal, incubate with modulator of inflammation, monitor animal for adjustment in inflammatory response |
12/28/2010 | US7858085 Reducing blood glucose level in a non-obese or obese human afflicted with Type 2 diabetes by administering purified human placental alkaline phosphatase |
12/28/2010 | US7858081 Peptide which is part of epitope in human IL-15 responsible for high-affinity binding of IL-15 to IL-15Ralpha chain, characterized in that it has sequence of region of human mature wild-type IL-15 from L44 to L52, or sequence of region of human mature wild-type IL-15 from E64 to I68 or from E64 to L69 |
12/23/2010 | WO2010147831A1 Dendrimer based nanodevices for therapeutic and imaging purposes |
12/23/2010 | WO2010147238A1 Agent for preventing or treating abnormality in skin water permeation function |
12/23/2010 | WO2010147145A1 Anti-gram-negative bacteria agent |
12/23/2010 | WO2010146634A1 Immunotherapeutic agent and immunotherapy for pancreatic cancer |
12/23/2010 | WO2010146478A1 Parenteral composition comprising a fluoroquinolone compound and a nitroimidazole compound |
12/23/2010 | WO2010146055A1 Antagonists of beta-catenin for preventing and/or treating neurodegenerative disorders |
12/23/2010 | WO2010145035A1 Renal cell carcinoma biomarkers |
12/23/2010 | WO2010095158A8 Pharmaceutical composition containing microcolloidal silver and carboxymethyl beta glucan for disinfection of the nasal mucosae, and process for preparation thereof |
12/23/2010 | WO2010080757A3 Combinations with an alpha-4beta-2 nicotinic agonist |
12/23/2010 | US20100325743 Marks as modifiers of the p53 pathway and methods of use |
12/23/2010 | US20100323987 Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
12/23/2010 | US20100323981 Treatment of statin side effects |
12/23/2010 | US20100323952 Nucleoside Analogs in Combination Therapy of Herpes Simplex Infections |
12/23/2010 | US20100323008 Solid dosage form comprising a fibrate |
12/23/2010 | US20100322902 Drug-containing sustained release microparticle, process for producing the same and preparation containing the microparticle |
12/23/2010 | US20100322899 Methods of improving central nervous system functioning |
12/23/2010 | US20100322853 Nanoparticulate compositions of angiogenesis inhibitors |
12/23/2010 | US20100322852 Nanoparticulate compositions of angiogenesis inhibitors |
12/23/2010 | CA2765870A1 Renal cell carcinoma biomarkers |
12/23/2010 | CA2765657A1 Anti-gram-negative bacteria agent |
12/23/2010 | CA2765408A1 New crystalline form of pemirolast |
12/22/2010 | EP2264172A1 Oligomeric compounds for the modulation of HIF-1alpha expression |
12/22/2010 | EP2264072A1 Enhancement of antibody-mediated cytotoxicity. |
12/22/2010 | EP2264064A1 Modified exendins and exendin agonists |
12/22/2010 | EP2264047A1 High purity lipopeptides, lipopeptide micelles and processes for preparing same |
12/22/2010 | EP2264032A2 Hiv protease inhibiting sulfonamides |
12/22/2010 | EP2264028A1 Pyrazole compounds useful as protein kinase inhibitors |
12/22/2010 | EP2263697A2 Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections |
12/22/2010 | EP2263695A2 Method and preparation for treating depressions |
12/22/2010 | EP2263694A1 Antitumor agent comprising the histone deacetylase inhibitor FK228 and a topoisomerase II inhibitor |
12/22/2010 | EP2263680A1 Compressed pharmaceutical compositions comprising PEG and electrolytes |
12/22/2010 | EP2263670A1 Use of angiotensin II receptor antagonists in order to increase insulin sensitivity |
12/22/2010 | EP2263652A1 Aerosols comprising nanoparticle drugs |
12/22/2010 | EP2263651A2 Low viscosity liquid dosage forms |
12/22/2010 | EP2263650A2 Nanoparticulate megestrol formulations |
12/22/2010 | EP2263649A1 Pharmacological adjuvants based on coordination compounds of d-metals |
12/22/2010 | EP2263648A1 Ophthalmic composition |
12/22/2010 | EP2263596A1 Dispensing apparatus and cartridge |
12/22/2010 | EP2263465A1 Polyvalent conjugate vaccine for cancer |
12/22/2010 | EP2262541A1 C2orf18 as target gene for cancer therapy and diagnosis |
12/22/2010 | EP2262535A1 Use of a composition containing healing earth as an antacid |
12/22/2010 | EP2262534A1 Palatable solid composition comprising antacid and saliva stimulant |
12/22/2010 | EP2262525A1 Apoaequorin-containing compositions and methods of using same |
12/22/2010 | EP2262502A1 Compositions and methods for alleviating depression or improving cognition |
12/22/2010 | EP2262492A2 Methods of treating hyperacidic disorders |
12/22/2010 | EP2262491A1 Therapy for disorders of the proximal digestive tract |
12/22/2010 | EP2262476A1 Drug delivery to the anterior and posterior segments of the eye using eye drops. |
12/22/2010 | EP1412317B1 Retinoid derivatives with antiangiogenic, antitumor and proapoptotic activities |
12/22/2010 | EP1390037B1 Use of glucocorticoid receptor-specific antagonists for the treatment of delirium |
12/22/2010 | EP1364660B1 Drug-releasing system of biodegradable polymer type |
12/22/2010 | EP1290182B1 Sphingosine kinase and uses thereof |
12/22/2010 | EP1214064B1 Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores |
12/22/2010 | EP1135496B1 Ucp5 |
12/22/2010 | CN1990045B Highly effective plaster for burn and scald and its preparation process |
12/22/2010 | CN1812973B Indazole compounds useful as protein kinase inhibitors |
12/22/2010 | CN1713926B Peritoneal dialysis method |
12/22/2010 | CN1547477B Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
12/22/2010 | CN1481390B Immunomodulatory peptides derived from heat shock proteins and uses thereof |
12/22/2010 | CN101925364A 14-3-3 antagonists for prevention and treatment of arthritis |
12/22/2010 | CN101925354A Anti-inflammatory compositions and combinations |
12/22/2010 | CN101921732A A virus causing respiratory tract illness in susceptible mammals |
12/22/2010 | CN101921347A Hyaluronic acid derivative and drug containing the same |
12/22/2010 | CN101921220A Remedies for diseases with bone mass loss having EP4 agonist as the active ingredient |
12/22/2010 | CN101920016A Implants for administering substances and methods of producing implants |
12/22/2010 | CN101920006A Cyclin Y and use thereof |
12/22/2010 | CN101919971A Agent for locally preventing and treating body surface diseases |
12/22/2010 | CN101919891A Scheme II safe anesthetic |